enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Atezolizumab - Wikipedia

   en.wikipedia.org/wiki/Atezolizumab

   Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [9] [11] but discontinued for use in triple-negative breast cancer (TNBC). [12]

3. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   Atezolizumab (Tecentriq) is a fully humanised IgG1 (immunoglobulin 1) antibody developed by Roche Genentech. In 2016, the FDA approved atezolizumab for urothelial carcinoma and non-small cell lung cancer. Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer.

4. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

5. Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

   www.aol.com/news/roches-tecentriq-gets-fda...

   Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

6. Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review - AOL

   www.aol.com/news/roches-tecentriq-sbla-lung...

   Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.

7. Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK ... - AOL

   www.aol.com/news/pharma-stock-roundup-fda...

   The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.

8. Atezolizumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Atezolizumab/hyaluronidase

   The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. [2]

9. Pfizer's bladder cancer therapy meets main goal in late-stage ...

   www.aol.com/news/pfizers-bladder-cancer-therapy...

   The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC ...